Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone

Pathol Oncol Res. 2020 Jul;26(3):1993-1995. doi: 10.1007/s12253-019-00725-x. Epub 2019 Aug 22.

Authors

Satoko Oka¹, Kazuo Ono², Masaharu Nohgawa³

Affiliations

¹ Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan. [email protected].
² Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan.
³ Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan.

PMID: 31440905
DOI: 10.1007/s12253-019-00725-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dexamethasone / therapeutic use
Humans
Lenalidomide / therapeutic use
Male
Multiple Myeloma / drug therapy*
Neoplasm Recurrence, Local / drug therapy*
Retreatment

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
elotuzumab
Dexamethasone
Lenalidomide